Industry Partnerships, Key Success Factor to Win in the Biosimilars Space
Requires Subscription or Fee PDF


business models


Over the past few years, biosimilars became the promised land of the pharmaceutical industry. Seven out of the top ten drugs are biologics. And all are about to lose patent protection by 2020, representing an underlying pool of $60bn branded sales. While it looks like the next Eldorado is in front of us, the biosimilars market is also a challenging opportunity, where the players have to deal with high R&D costs, unclear regulatory pathways, and uncertainty around business models. To make the biosimilars opportunity a sustainable market, it has to be profitable. In this article, I would like to discuss how innovative business models can help biosimiliars players to de-risk and ensure profitability. Looking at the example of the airline industry and analyzing the development chain for biosimilars, I would like to propose options to de-risk investments, optimize costs, and maximize sales.
Requires Subscription or Fee PDF

Unless specified by prior arrangement, the author agrees to the following terms and assurances:

  1. For myself and on behalf of the other authors listed on this work, I assign to thinkBiotech LLC the copyright* in the contribution for the full term throughout the world.
  2. I/we further give to the following assurances
    1. I am the sole author of the contribution, or, if not, I have the written authority of the other authors to transfer the copyright* to thinkBiotech LLC and give these warranties;
    2. I and (where appropriate) the other authors are entitled to transfer the copyright to thinkBiotech LLC and no one else would be entitled to prevent us from publishing the contribution;
    3. To the best of my/our knowledge, all the facts in the contribution are true and accurate;
    4. The content of the contribution is entirely original to me (and where appropriate to the other authors) or, if not, the written permission of the owner of the copyright in any material copied from elsewhere has been obtained for all media (all such permissions to be attached to the contribution as supplementary files);
    5. Nothing in the contribution is obscene or libellous;
    6. Nothing in the contribution infringes any duty of confidentiality which I/or the other authors may owe to anyone else.
    7. I and/or the other authors have obtained the appropriate clearances from my/our employer(s) or other concerned institution(s).
* Works by US government employees prepared as part of official duties are in the public domain and the authors are therefore exempt from copyright assignment.